抑制mTOR的抗肿瘤药物的研究进展  

Sudy on the Development of mTOR Inhibitors of Anti-Tumor Medicine

作　　者：张辉[1] 胡逢恺[1] 

机构地区：[1]黄山学院化学系,安徽黄山245041

出　　处：《黄山学院学报》2007年第3期66-70,共5页Journal of Huangshan University

基　　金：黄山学院自然科学研究项目(2006xkj004)

摘　　要：mTOR受体蛋白是真核细胞中存在的一种PIKK类的激酶,它在细胞分裂、分化、生存中起着核心的作用,对mTOR的抑制将使细胞停滞于G1期或使细胞凋亡。现在已经开发出来的mTOR抑制剂有雷帕霉素衍生物、吡咯并喹啉衍生物及色酮类衍生物,它们的活性研究表明mTOR抑制剂有望成为一类新型抗肿瘤药物。The mTOR receptor protein is a sort of PIKK kinases existing in the eukaryotic cell.It plays a core role in the cell division,differentiation and survival.The mTOR suppression will cause G1-arresting or perishing to the cells.Currently,we have already developed rapamycin derivatives,the pyrrole-quinoline derivatives and the colorketones derivatives as mTOR inhibitor.Studys on Reactivity of these mTOR inhibitors indicate they have much prospect to be a new kind of anti-tumor medicine.

关 键 词：MTOR 雷帕霉素 PIKK FKBP 吡咯并喹啉 色酮 

分 类 号：TQ464.8[化学工程—制药化工]